Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Public ClinicalTrials.gov record NCT04195633. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation work in treating patients with blood cancers (hematological malignancies). Giving chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient, they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. The donated stem cells may also replace the patient's immune cells and help destroy any remaining cancer cells.
Study identification
- NCT ID
- NCT04195633
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Conditions
- Acute Leukemia
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Adult Diffuse Large Cell Lymphoma
- Anaplastic Large Cell Lymphoma
- Burkitt Lymphoma
- Chronic Myeloid Leukemia, BCR-ABL1 Positive
- Chronic Myelomonocytic Leukemia
- Hodgkin Lymphoma
- Lymphoblastic Lymphoma
- Lymphoplasmacytic Lymphoma
- Mantle Cell Lymphoma
- Mixed Phenotype Acute Leukemia
- Myelodysplastic Syndrome
- Prolymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia
- Refractory Follicular Lymphoma
- Refractory Marginal Zone Lymphoma
- Refractory Small Lymphocytic Lymphoma
Interventions
- Allogeneic Hematopoietic Stem Cell Transplantation Procedure
- Cyclophosphamide Drug
- Cyclosporine Drug
- Filgrastim Biological
- Fludarabine Drug
- Mycophenolate Mofetil Drug
- Mycophenolate Sodium Drug
- Total-Body Irradiation Radiation
- Treosulfan Drug
- Bone Marrow Aspiration Procedure
- Bone Marrow Biopsy Procedure
- Echocardiography Test Procedure
- Biospecimen Collection Procedure
- Computed Tomography Procedure
- Positron Emission Tomography Procedure
Procedure · Drug · Biological + 1 more
Eligibility (public fields only)
- Age range
- 6 Months and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 24, 2021
- Primary completion
- Apr 14, 2027
- Completion
- Mar 11, 2029
- Last update posted
- May 28, 2026
2021 – 2029
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04195633, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 28, 2026 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04195633 live on ClinicalTrials.gov.